東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

The SYK Tyrosine Kinase Suppresses A...

Hua, Kevin L.

FindBook

Google Book

Amazon

博客來

The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines./
作者:	Hua, Kevin L.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	193 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-05, Section: B.
Contained By:	Dissertations Abstracts International81-05B.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13887265
ISBN:	9781687952073

The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines.
Hua, Kevin L.

The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 193 p.

Source: Dissertations Abstracts International, Volume: 81-05, Section: B.

Thesis (Ph.D.)--Boston University, 2019.

This item must not be sold to any third party vendors.

Spleen tyrosine kinase (SYK) regulates mitogenic signaling, inflammatory responses and cell fate in a number of diverse cell types. KRAS is a proto-oncogene that controls cell growth and proliferation through several mitogenic pathways. In pancreatic cancer, KRAS is frequently mutated, resulting in constitutive activation in 90% of pancreatic cancer cell lines. We previously showed that SYK is highly expressed in a subset of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cell lines. We demonstrated that SYK kinase inhibition with PRT062607 (SYKi) causes decreased cell proliferation of PDAC cell lines. Furthermore, combined SYKi and MEK inhibitor (MEKi) treatment promotes additive effects on suppression of PDAC cell proliferation and clonogenic growth. Mechanistically, SYK activates the mTORC1 kinase complex as shown by reduced phosphorylation of ribosomal S6 protein and its upstream kinase p70 S6 kinase (p70S6K) following SYKi treatment in PDAC cell lines. SYK-mediated mTORC1 activation occurs independently of MEK/ERK and PI3K/AKT effector signaling pathways. The mTORC1 complex suppresses lysosome biogenesis and macroautophagy (autophagy). Consequently, mTORC1 suppression via SYK inhibition or shRNA-mediated depletion causes accumulation of autolysosomes. These effects are mediated by the enhanced nuclear localization of MITF, a key transcriptional regulator of genes involved in lysosome biogenesis and autophagy pathway activation. In summary, SYK positively regulates mTORC1 activation in a subset of PDAC cell lines to suppress hyperactivation of autophagy. These findings open new avenues for further exploration of SYK as a critical regulator of the autophagy pathway in KRAS/mTORC1-dependent PDAC, and how this may be exploited for therapeutic benefit.

ISBN: 9781687952073Subjects--Topical Terms:

517296
Molecular biology.
Subjects--Index Terms:

Autophagy

The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines.
LDR:03022nmm a2200409 4500 001 2272589
005 20201105110131.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781687952073
035 $a (MiAaPQ)AAI13887265
035 $a AAI13887265
040 $a MiAaPQ $c MiAaPQ
100 1 $a Hua, Kevin L. $3 3550019
245 1 4 $a The SYK Tyrosine Kinase Suppresses Autolysosome Biogenesis via Activation of mTORC1 in Pancreatic Cancer Cell Lines.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 193 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-05, Section: B.
500 $a Advisor: Singh, Anurag.
502 $a Thesis (Ph.D.)--Boston University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Spleen tyrosine kinase (SYK) regulates mitogenic signaling, inflammatory responses and cell fate in a number of diverse cell types. KRAS is a proto-oncogene that controls cell growth and proliferation through several mitogenic pathways. In pancreatic cancer, KRAS is frequently mutated, resulting in constitutive activation in 90% of pancreatic cancer cell lines. We previously showed that SYK is highly expressed in a subset of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cell lines. We demonstrated that SYK kinase inhibition with PRT062607 (SYKi) causes decreased cell proliferation of PDAC cell lines. Furthermore, combined SYKi and MEK inhibitor (MEKi) treatment promotes additive effects on suppression of PDAC cell proliferation and clonogenic growth. Mechanistically, SYK activates the mTORC1 kinase complex as shown by reduced phosphorylation of ribosomal S6 protein and its upstream kinase p70 S6 kinase (p70S6K) following SYKi treatment in PDAC cell lines. SYK-mediated mTORC1 activation occurs independently of MEK/ERK and PI3K/AKT effector signaling pathways. The mTORC1 complex suppresses lysosome biogenesis and macroautophagy (autophagy). Consequently, mTORC1 suppression via SYK inhibition or shRNA-mediated depletion causes accumulation of autolysosomes. These effects are mediated by the enhanced nuclear localization of MITF, a key transcriptional regulator of genes involved in lysosome biogenesis and autophagy pathway activation. In summary, SYK positively regulates mTORC1 activation in a subset of PDAC cell lines to suppress hyperactivation of autophagy. These findings open new avenues for further exploration of SYK as a critical regulator of the autophagy pathway in KRAS/mTORC1-dependent PDAC, and how this may be exploited for therapeutic benefit.
590 $a School code: 0017.
650 4 $a Molecular biology. $3 517296
650 4 $a Biology. $3 522710
650 4 $a Cellular biology. $3 3172791
650 4 $a Physiology. $3 518431
650 4 $a Oncology. $3 751006
650 4 $a Health sciences. $3 3168359
653 $a Autophagy
653 $a MITF
653 $a mTOR
653 $a Pancreatic cancer
653 $a Spleen tyrosine kinase
690 $a 0307
690 $a 0306
690 $a 0379
690 $a 0566
690 $a 0992
690 $a 0719
710 2 $a Boston University. $b Pharmacology GMS. $3 3543270
773 0 $t Dissertations Abstracts International $g 81-05B.
790 $a 0017
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13887265